Press Releases

AVROBIO, Inc. Announces $60 Million Series B Financing to Advance Gene Therapy Pipeline for Lysosomal Storage Disorders and Apply Lentiviral Platform to Other Genetic Diseases

Company to initiate Phase 2 trial with lead gene therapy, AVR-RD-01, based on promising initial clinical data in Fabry disease Strong investor syndicate supports multi-product portfolio with three additional gene therapies for Gaucher disease, cystinosis and Pompe disease Cambridge, Mass., February

Read More »
Displaying 11 - 12 of 12